Loading…
Active site-directed inactivation of constitutively active mutants of rhodopsin
Recently, mutations of the active site Lys296 residue in rhodopsin (Lys296-->Glu and Lys296-->Met) have been found as the cause of disease in some patients with autosomal dominant retinitis pigmentosa. In vitro, these mutations result in constitutive activation of the protein. In an effort to...
Saved in:
Published in: | The Journal of biological chemistry 1994-03, Vol.269 (9), p.6524-6527 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Recently, mutations of the active site Lys296 residue in rhodopsin (Lys296-->Glu and Lys296-->Met) have been found as the
cause of disease in some patients with autosomal dominant retinitis pigmentosa. In vitro, these mutations result in constitutive
activation of the protein. In an effort to develop a potential therapeutic agent for treatment of the disease, we have examined
various amine derivatives of 11-cis- and 9-cis-retinal for ability to irreversibly inactivate a related constitutively active
mutant, K296G. Three amines were prepared by reductive amination of retinal: 11-cis-retinylpropylamine, 11-cis-retinylamine,
and 9-cis-retinylamine. All three compounds inactivated K296G, and the inactivation could not be reversed upon exposure to
light. None of the compounds inactivated the wild-type protein. Although the amines were not effective on the naturally occurring
retinitis pigmentosa mutants, presumably because of unfavorable steric interactions with the bulky Glu and Met side chains
at position 296, the success with K296G makes it highly encouraging that this approach will evolve related compounds that
are capable of inactivating the naturally occurring mutants as well. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1016/S0021-9258(17)37403-3 |